Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Neoplasms 287Breast Neoplasms 280Lung Neoplasms 134Prostatic Neoplasms 125Colorectal Neoplasms 113Carcinoma, Non-Small-Cell Lung 109Pancreatic Neoplasms 73Carcinoma, Hepatocellular 56Stomach Neoplasms 54Hematologic Neoplasms 53Brain Neoplasms 53Ovarian Neoplasms 52Urinary Bladder Neoplasms 49Multiple Myeloma 49Leukemia, Myeloid, Acute 48Esophageal Neoplasms 47Melanoma 46Disease 43Head and Neck Neoplasms 40Colonic Neoplasms 40Rectal Neoplasms 37Liver Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 36Neoplasm Metastasis 36Lymphoma 33Uterine Cervical Neoplasms 32Endometrial Neoplasms 32Leukemia, Lymphocytic, Chronic, B-Cell 31Thyroid Neoplasms 29Recurrence 29

Interventions

Mass Screening 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Pulmonary Atelectasis × 90 days × Clear all
NCT04663958 2026-04-30

Predictive Value of Ariscat Index In The Development of Pulmonary Complication After Major Abdominal Cancer Surgery

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital

Completed
410 enrolled

Pulmonary Atelectasis, Neoplasms, Pneumonia, Postoperative Complications

Data powered by HemOnc (CC BY 4.0) Colophon âš¡